GuidelineClinical journal of the American Society of Nephrology : CJASN2015
Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.
Guideline in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01).Clinical and translational science · 2020Trial
- Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.European journal of clinical pharmacology · 2016Trial
- User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients With Kidney Impairment-A Case Series.Pharmacotherapy · 2026Article
- From Intelligent Operating Room to Smart ICU: Digital Continuity, AI-Supported Decision-Making and CRRT as a Model of Pharmacokinetic Personalization in Critical Care.Healthcare (Basel, Switzerland) · 2026Review
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Development and validation of a machine learning model for individualised meropenem dosing in CRRT patients.Scientific reports · 2026Article
- Interaction of milrinone with extracorporeal life support.The journal of extra-corporeal technology · 2024Article
- Medication patterns and dosing guidance in pediatric patients supported with intermittent hemodialysis or continuous kidney replacement therapy.Pediatric nephrology (Berlin, Germany) · 2024Review
- Meropenem extraction by ex vivo extracorporeal life support circuits.The journal of extra-corporeal technology · 2023Article
- Direct and continuous dosing of propofol can saturate Ex vivo ECMO circuit to improve propofol recovery.The journal of extra-corporeal technology · 2023Article
- Cefepime Extraction by Extracorporeal Life Support Circuits.The journal of extra-corporeal technology · 2022Article
- Remdesivir and GS-441524 Extraction by Ex Vivo Extracorporeal Life Support Circuits.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2022Article
- Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy.Critical care explorations · 2022Review
- Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy.Pharmaceutical research · 2022Article
- A Clinician's Guide to Dosing Analgesics, Anticonvulsants, and Psychotropic Medications in Continuous Renal Replacement Therapy.Kidney international reports · 2021Review
- Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.International journal of clinical pharmacy · 2018Article
- Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.European journal of clinical pharmacology · 2017Article
- The future of critical care: renal support in 2027.Critical care (London, England) · 2017Review
- What Do We Know about Opioids and the Kidney?International journal of molecular sciences · 2017Review
- Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.Clinical drug investigation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of AKI and modern continuous RRT (CRRT) methods on drug disposition (pharmacokinetics) and response has been poorly studied. Pharmaceutical manufacturers have little incentive to perform pharmacokinetic studies in patients undergoing CRRT because such studies are neither recommended in existing US Food and Drug Administration (FDA) guidance documents nor required for new drug approval. Action is urgently needed to address the knowledge deficit. The Kidney Health Initiative has assembled a work group composed of clinicians and scientists representing academia, the FDA, and the pharmaceutical and dialysis industries with expertise related to pharmacokinetics, AKI, and/or CRRT. The work group critically evaluated key considerations in the assessment of pharmacokinetics and drug dosing in CRRT, practical constraints related to conducting pharmacokinetic studies in critically ill patients, and the generalizability of observations made in the context of specific CRRT prescriptions and specific patient populations in order to identify efficient study designs capable of addressing the knowledge deficit without impeding drug development. Considerations for the standardized assessment of pharmacokinetics and development of corresponding drug dosing recommendations in critically ill patients with AKI receiving CRRT are proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.